二甲双胍与艾塞那肽治疗新诊断2型糖尿病的疗效及其对血糖波动的影响

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (554 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the effect of exenatide and metformin on treatment of newly diagnosed type 2 diabetes.Methods 68 patients with newly diagnosed type 2 diabetes were randomly divided into two groups: metformin group (35 patients) and exenatide group (33 patients) and were treated for 12 weeks. The changes in FBG, 2 h PG, HbA₁c, CHO, TG, LDL, BMI, MAGE, LAGE and MPPGE were observed in two groups.Results After 12 weeks of treatment, in two groups the levels of FBG, 2 h PG, HbA₁c, MAGE, LAGE and MPPGE showed significant decrease (P<0.05), and no significant difference was observed. After treatment,TG was significantly lower than before treatment in the two groups (P<0.05), TG was (1.88±0.57) mmol/L in metformin group and (1.58±0.21) mmol/L in exenatide group; compared with metformin group, in the exenatide group it decreased more significantly (P<0.05). In exenatide group, body mass index (BMI) was (25.14±2.21) kg/m² before treatment and (23.16±1.46) kg/m² after treatment, BMI was significantly decreased after treatment (P<0.05).Conclusions In patients with newly diagnosed type 2 diabetes, exenatide and metformin can remarkably control blood glucose. The effect of exenatide on body weight and TG are better than that of metformin.

Key words： exenatide metformin type 2 diabetes glucose fluctuation

Received: 23 March 2016

ZTFLH:

R587

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Xingguang
	WU Jinxiao
	CHENG Qianpeng
	and SU Ximing

Cite this article:

ZHANG Xingguang,WU Jinxiao,CHENG Qianpeng等. Efficacy of metformin and exenatide in newly diagnosed type 2 diabetes and their effect on glucose fluctuation[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(8): 823-825.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2016/V27/I8/823

[1]	Sierra P R, Riobó S P, Vázquez M C. Effects of exenatide lar in type 2 diabetes mellitus and obesity [J]. Nutr Hosp, 2014, 31(1): 292-298.
[2]	李静,陈宏,张桦,等.艾塞那肽对间歇性高糖环境下胰岛INS-1细胞的保护作用[J]. 解放军医学杂志, 2011, 36(4): 379-381.
[3]	Gallwitz B. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents [J]. Drugs,2011,71(13):1675-1688.
[4]	Bhavsar S,Mudaliar S,Cherrington A. Evolution of exenatide as a diabetes therapeutic[J].Curr Diabetes Rev,2013,9(2):161-193.
[5]	Pujante A P,Hellín G,Roman L M,et al. Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide [J]. Med Clin (Barc),2012,139(13):572-578.
[6]	Torimoto K, Okada Y, Mori H, et al. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus [J]. Cardiovasc Diabetol, 2013,12(1):1-7.
[7]	Lv X, Zhang X, Zhang Y, et al. The impact of blood glucose fluctuation on endothelial dysfunction and severity of stenosis in acute coronary syndrome patients [J]. Exp Clin Cardiol,2014,20(1):1747-1761.
[8]	Huang J,Zhang X,Li J,et al.Impact of glucose fluctuation on acute cerebral infarction in type 2 diabetes[J]. Can J Neurol Sci,2014,41(4):486-492.
[9]	Jiao X M,Zhang X G,Xu X U,et al. Blood glucose fluctuation aggravates lower extremity vascular disease in type 2 diabetes [J]. Eur Rev Med Pharmacol Sci,2014,18(14):2025-2030.
[10]	Matsuo K,Nambu T,Matsuda Y,et al.Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy [J]. Intern Med,2013,52(1):89-95.